Citations

Clear

1056 citation(s) found for "Sharma, P".

Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Abstract B065: Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type
Hegde, Apurva M. , Garcia-Masnfield, Krystine, Alcantara, Marice , ROSE, D. L. , Halperin, Rebecca F. , David‐Dirgo, Victoria , Facista, Salvatore , Moore, Rayvon , Kofman, Rochelle , Jensen, Zoe N. , Zismann, Victoria , Hendricks, William P.D. , Huntsman, David G. , Rodrı́guez-Rodrı́guez, Lorna , Weissman, Bernard E. , Trent, Jeffrey M. , Pirrotte, Patrick , Raupach, Elizabeth A. , Rose, David, Orlando, Krystal A. , Lang, Jessica, Sharma, Ritin , Karnezis, Anthony N. , Wang, Yemin , Bennett, Lynda , Whitsett, Timothy G. , Kortylewski, Marcin T.

Mayo Clinic

Cancer Research | September 19, 2025 | Volume: 85 | Issue: 18_Supplement | Pages: B065-B065

10.1158/1538-7445.ovarian25-b065 Get It

Abstract Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. Here, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared to normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune reactive tumor microenvironment. Mutations in several SWI/SNF subunits were associated with higher rates of outlier retained introns across tumor types in TCGA data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention. Distinct protein-protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Further, SWI/SNF localized to genes which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFa and INFb in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to intron retention. Furthermore, T cell activation by novel peptides encoded by these tumor-specific splicing events suggests intron retention could be a source of tumor-associated antigens in SCCOHT. Citation Format: Elizabeth Raupach, Apurva Hegde, Krystine Garcia-Masnfield, Marice Alcantara, David Rose, Rebecca Halperin, Krystal Orlando, Jessica Lang, Ritin Sharma, Victoria David-Dirgo, Salvatore Facista, Rayvon Moore, Rochelle Kofman, Zoe Jensen, Victoria Zismann, Anthony Karnezis, Yemin Wang, Lynda Bennett, Timothy Whitsett, Marcin Kortylewski, William Hendricks, David Huntsman, Lorna Rodriguez-Rodriguez, Bernard Weissman, Jeffrey Trent, Patrick Pirrotte. Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B065.
Trends and Outcomes of Secondary Intraocular Lens Utilization Among Vitreoretinal Surgeons Compared to Vitreoretinal and Anterior Segment Surgeons
Aggarwal, Nitika, Boucher, Nicholas, Sharma, Chakshu, Bantounou, Maria Anna , Boucher, Nicholas, Starr, Matthew R.

Mayo Clinic

Ophthalmic Surgery, Lasers and Imaging Retina | September 15, 2025 | Volume: 56 | Issue: 10 | Pages: 602-607

10.3928/23258160-20250725-01 | PMID 40952683 Get It

Background and Objective: Scleral-fixated intraocular lens (SFIOL), scleral-sutured IOL (SSIOL), anterior chamber IOL (ACIOL) are used to manage aphakia or lens subluxation. This study compared trends in surgical techniques and outcomes of secondary IOL implantation based on surgeon type. Patients and Methods: This retrospective study included patients from United States (US) retinal centers who underwent surgery by vitreoretinal (VR cohort) or VR and anterior segment (AS) (combined cohort) surgeons from 2015 to 2024. Complications assessed included retinal detachment, endophthalmitis, suture erosion, haptic erosion, repeat pas plana vitrectomy, and corneal edema. Results: VR surgeons performed 4,143 secondary IOL surgeries (1,977 ACIOL, 1,327 SFIOL, 839 SSIOL) while VR and AS surgeons performed 511 (342 ACIOL, 125 SFIOL, 44 SSIOL). SFIOL and SSIOL surgeries by VR surgeons increased, whereas ACIOL surgeries decreased. VR and AS surgeons maintained a steady but lower volume of SFIOL and SSIOL cases, with increasing ACIOL surgeries. Postoperative visual acuity for the VR and combination cohorts was 54.3 ± 27.8 and 51.5 ± 27.2 (≈ 20/100 Snellen) ( P value = 0.102), respectively. Complication rates were similar between cohorts, except for postoperative retinal detachment (VR: 144, 3.5%; combined: 26, 5.1%; P value < 0.001). Conclusion: ACIOLs were the most commonly performed secondary IOL surgery. However, a shift toward SFIOL and SSIOL techniques among vitreo-retinal surgeons emerged. Outcomes were comparable between approaches.
Impact of Gender of the Child on Health Care–Seeking Behavior of Caregivers of Childhood Patients With Cancer: A Mixed-Methods Study
Bhatia, Kanu Priya , Ganguly, Shuvadeep , Sasi, Archana , Singh, Manraj , Malhotra, Sumit , Sharma, Shubhangi , Tahiliani, Bhavika , Verma, Vasudha , Dhania, Tripti, Bisht, Reema, Sharma, Swetambri , Kumari, Mamta , Agarwala, Sandeep , Satapathy, Sujata , Bakhshi, Sameer , Sra, Manraj Singh , Pushpam, Deepam , Bakhshi, Sameer , Verma, Vasudha , Pushpam, Deepam

Mayo Clinic

JCO Global Oncology | September 9, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-24-00325 | PMID 40924975 Get It

PURPOSE Gender bias against girls may affect health-seeking behavior and outcomes of childhood cancer. This study aimed to study the nature and extent of gender bias in health care among caregivers of childhood patients with cancer and also in community. METHODS This cross-sectional mixed-methods study was conducted in a tertiary cancer hospital and an urban community between July 2021 and July 2023. Qualitative component included 26 in-depth interviews (IDI) and four focus group discussions (FGDs) with caregivers of children with cancer. IDIs and FGDs were conducted by a psychologist and continued until thematic saturation was reached. For quantitative part, a gender-bias questionnaire was finalized which was administered to 230 caregivers in hospital and 311 participants from the community, with children in family. RESULTS Most participants did not perceive personal gender bias; however, many acknowledged noticing gender bias in others. This bias was linked to girls being considered financial burdens and having reduced marital prospects due to illness. Reducing treatment costs, improving access, and education targeting societal mindsets were suggested measures to mitigate bias. In community, no significant difference was observed among the respondents based on sex of youngest child in family. However, in hospital, caregivers of male children were less likely to offer similar care to a child of opposite sex than that reported by caregivers of female children ( P = .01) for ailments like fever/diarrhea. Similar difference was not observed for other health care scenarios. CONCLUSION Gender bias against girls, including that in health care access, is influenced by societal norms. Even with little personal perception of bias, there was a significant perceived bias observed in others by the participants. This study identified the existence of gender bias affecting health care choices, including cancer care.
Rising Obesity-Related Cardiovascular Mortality in the United States, 1999–2020: Accelerating Trends and Widening Disparities
Pavuluri, Sai Swetha, Kataveni, Suhas , Trivedi, Shashank , Pasupuleti, Suman, Sahai, Akshat, Haidar, Salar, Vashisht, Kumar, Adithya, Vikram, Lanka, Nidhi, Sharma, Gaurav , Pasupuleti, Suman, Sahai, Akshat, Haidar, Salar

Mayo Clinic

No container title available | September 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7530128/v1 Get It

Abstract Obesity is a major and growing driver of cardiovascular disease (CVD) in the United States, contributing to hypertension, diabetes, dyslipidemia, and structural cardiac changes that elevate the risk of ischemic heart disease, heart failure, and stroke. After decades of declining CVD mortality, recent national trends show a concerning reversal, coinciding with record-high obesity prevalence. We quantified national trends and disparities in obesity-related CVD mortality from 1999–2020 using de-identified death certificate data from the CDC WONDER database for U.S. residents aged 15–84 years, including deaths with circulatory disease (ICD-10 I00–I99) as the underlying cause and obesity (E66.0–E66.9) as a contributing cause. Age-adjusted mortality rates (AAMR) standardized to the 2000 U.S. population were analyzed using joinpoint regression to estimate annual percent change (APC) and detect inflection points. From 1999–2018, AAMR rose from 2.75 to 6.61 per 100,000 (APC 4.79%; 95% CI 4.60–4.98), followed by a significant post-2018 acceleration (APC 11.05%; 95% CI 6.76–15.51) to 8.36 in 2020. Mortality was highest among adults 65–74 years, males, Black Americans, and nonmetropolitan residents, with a 5.1-fold state variation. Young adults (15–24 years) had the largest relative increase (+210%). The 2020 surge was independent of COVID-19 mortality, indicating gaps in chronic disease management. These results highlight a growing obesity-related CVD mortality burden, with widening disparities by age, sex, race, and geography, emphasizing urgent, equity-focused prevention and targeted interventions.
ACR–ABS–ACNM–ARS–SIR–SNMMI Practice Parameter for Radioembolization of Liver Malignancies
Johnson, Thor, Spieler, Benjamin , Toskich, Beau , Wang, David S. , Russo, Suzanne , Sharma, Navesh , Wright, Chadwick , Farsad, Khashayar , Muzahir, Saima , Chundury, Anupama , Subramaniam, Rathan M. , Caplin, Drew M. , Schechter, Naomi R., Toskich, Beau B. , Hathout, Lara , Russo, Suzanne , Kim, Charles , Kappadath, Srinivas Cheenu , Parent, Ephraim E. , Sio, Terence T. , Mercier, Gustavo , Ghesani, Munir V. , Small, William

Mayo Clinic

American Journal of Clinical Oncology | September 3, 2025 | Volume: 49 | Issue: 1 | Pages: 10-24

10.1097/coc.0000000000001234 | PMID 40899409 Get It

Objectives: The practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Interventional Radiology (SIR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This document summarizes current evidence-based guidelines for the administration of Yttrium radioembolic therapy to the liver, including training requirements, evidence-based guidelines for administration, and safe practice for administration. Methods: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Interventional and Cardiovascular Radiology of the ACR Commission on Interventional and Cardiovascular, Committee on Practice Parameters and Technical Standards—Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ABS, the ACNM, the ARS, the SIR, and the SNMMI. Results: This review seeks not to be a comprehensive discussion of radiotherapy to the liver, but rather, seeks to provide a parameter for safe and effective therapy. We discuss the qualifications of physicians involved in this therapy, basic indications, contraindications, procedural work-up, safe-handling, and regulatory requirement for the administration of selective internal radiation therapy to patients that are likely to benefit. The goal of this document is not to define which patients are best treated by these therapies, as this is best determined for individual patients after multidisciplinary review. A consistent and evidence-based approach to therapy, however, would benefit all patients who are offered this therapy. This document seeks to provide a framework for current best practices for the administration of the 2 currently available radioembolization devices. Conclusions: As Yttrium-90 radiotherapy to the liver occupies a growing role in the treatment of primary and metastatic liver cancer, this review seeks to assist clinicians of all involved specialties to optimize the efficacy and safety of these procedures.
Inpatient and Outpatient Radiology Report Access After the 21st Century Cures Act
Tariq, Amara , Schmitz, John J. , Varner, Jacob, Metcalfe, Allie M., Pollock, Jordan Riley , Sharma, Umesh, Tan, Nelly

Mayo Clinic

JAMA Network Open | August 27, 2025 | Volume: 8 | Issue: 8 | Pages: e2528683

10.1001/jamanetworkopen.2025.28683 | PMID 40864472 Get It

This cohort study examines trends in patient access of radiology imaging results after implementation of the 21st Century Cures Act in different clinical settings.
Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus and Esophageal Cancer Using a Modified Delphi Process
Shah, Tilak , Ansari, Zaid , Ahmad, Akram I. , Coyle, Walter , Greenwald, Bruce B., Kachaamy, Toufic , Kothari, Shivangi , Sharma, Neil , Smallfield, George , Thakkar, Shyam , Tsai, Franklin , Zhang, Han , Friedland, Shai , Mok, Shaffer , Sedarat, Alireza, Smith, Michael S. , Vashi, Pankaj G., Fukami, Norio , Mok, Shaffer , Smith, Michael , Willingham, Field F , Turshudzhyan, Alla , Kaul, Vivek , Greenwald, Bruce B., Fukami, Norio , Vargo, John Joseph , Willingham, Field F.

Mayo Clinic

American Journal of Gastroenterology | August 26, 2025 | Volume: 121 | Issue: 7 | Pages: 1592-1599

10.14309/ajg.0000000000003752 | PMID 40856659 Get It

INTRODUCTION: The study aimed to develop consensus recommendations for the safe and appropriate use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. METHODS: Statements were initially formulated and grouped into categories of indications, training, preprocedure, intraprocedure, and postprocedure recommendations, frequency/timing of repeat procedures, and contraindications. Two investigators assessed the strength of the evidence for each statement using Grading of Recommendations Assessment, Development, and Evaluation methodology. Nineteen experts were invited to participate in a modified Delphi process. For statements that received >80% agreement, minor iterative edits were performed until there was unanimous consensus. If a threshold of 80% agreement was not reached, the statement was modified based on feedback and included in the next Delphi round. Statements were rejected if no consensus was reached after 3 rounds. RESULTS: After 3 Delphi rounds, 41 of 42 statements were accepted either in their original version (n = 11) or after modification based on expert input (n = 30). DISCUSSION: Through a modified Delphi process, we developed expert and evidence-based consensus recommendations to guide safe and appropriate use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer.
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Lurz, Philipp , Hahn, Rebecca T. , Kodali, Susheel , Makkar, Raj , Sharma, Rahul , Davidson, Charles J. , O’Neill, Brian , Yadav, Pradeep , Zahr, Firas , Chadderdon, Scott , Eleid, Mackram F. , Smith, Robert L, Garcia, Santiago , Kister, Tobias , Kipperman, Robert, Lim, Scott, Hermiller, James, Mishell, Jacob M. , Rassi, Andrew N., Szeto, Wilson Y. , Babaliaros, Vasilis , Barker, Colin M. , Summers, Matthew , Chetcuti, Stanley, Ailawadi, Gorav , Russo, Mark, Rinaldi, Michael, Chehab, Bassem , Nickenig, Georg, Stinis, Curtiss, Inglessis‐Azuaje, Ignacio , Dhoble, Abhijeet , Petrossian, George , Shah, Pinak, Staniloae, Cezar , Nores, Marcos, Singh, Gagan D. , Baldus, Stephan , Rudolph, Volker , Barb, Ilie, Klodell, C.T., Gray, William A. , Strote, Justin A, Sannino, Anna , Grayburn, Paul , Mack, Michael J. , Leon, Martin B. , Thourani, Vinod H. , Lim, D. Scott , Szerlip, Molly , Kister, Tobias , Lim, D Scott , Saxon, John , Kapadia, Samir , Mishell, Jacob M , Herrmann, Howard C , Hausleiter, Jörg , Babaliaros, Vasilis , Barker, Colin M , Lindman, Brian R , Latib, Azeem , von Bardeleben, Ralph Stephan , Summers, Matthew , Ailawadi, Gorav , Rinaldi, Michael , Chehab, Bassem M , Nickenig, Georg , Inglessis-Azuaje, Ignacio , Dhoble, Abhijeet , Chhatriwalla, Adnan K , Petrossian, George , Shah, Pinak , Staniloae, Cezar , Williams, Mathew , McCabe, James M , Singh, Gagan , Baldus, Stephan , Rudolph, Volker , Klodell, Charles , Gray, William , Strote, Justin , Sannino, Anna , Grayburn, Paul , Mack, Michael J , Thourani, Vinod H , Davidson, Charles J. , Hahn, Rebecca T , Lurz, Philipp , Smith, Robert L, Whisenant, Brian K. , Kapadia, Samir , Hausleiter, Jörg , Lindman, Brian R. , Latib, Azeem , Muhammad, Kamran I. , Williams, Mathew

Mayo Clinic

European Heart Journal | August 21, 2025 | Volume: 47 | Issue: 17 | Pages: 2059-2073

10.1093/eurheartj/ehaf676 | PMID 40878717 Get It

Abstract Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.